|Minimum Order Quantity
|Intas Pharmaceuticals Ltd
|Country of Origin
|Made in India
Introduction to Pth 30mg Tablet
PTH 30mg Tablet is a calcimimetic medication containing the active ingredient Cinacalcet. This medication is used to treat hyperparathyroidism (overactivity of the parathyroid glands, which are small glands located in the neck) in patients with chronic kidney disease who are on dialysis. It is also used to treat hypercalcemia in patients with parathyroid carcinoma (a rare type of cancer that develops in the parathyroid glands). It helps regulate the levels of parathyroid hormone (PTH) in the body.
Before consuming this drug, inform your physician if you have had liver or heart failure or heart rhythm problems and have a history of seizures (fits or convulsions), as the risk of having seizures might be higher if you've experienced them. PTH 30mg Tablet should not be taken by children under the age of 18 who have parathyroid cancer or primary hyperparathyroidism. This medication is not suitable for this age group for these conditions. If you are receiving treatment for secondary hyperparathyroidism, your doctor will carefully monitor your calcium levels before you start using the drug and throughout your treatment with the medication.
Uses of Pth 30mg Tablet
Treatment of hyperparathyroidism
Safety Advices for Pth 30mg Tablet
If you are pregnant, suspecting, or planning for the pregnancy, report to your doctor before starting the treatment with PTH 30mg Tablet.
It is unknown whether PTH 30mg Tablet is excreted in breast milk. If you are breastfeeding, consult to your doctor before starting the treatment with this drug.
It is unknown whether PTH 30mg Tablet is safe for patients with lung problems. Inform your physician if you have any lung disease before starting the treatment
PTH 30mg Tablet should be cautiously used in patients with severe liver diseases. Dose adjustments are necessary. Inform your doctor if you have liver issues before initiating the therapy.
It is unknown whether consuming alcohol interacts with PTH 30mg Tablet. Please consult your doctor for more advice.
Driving vehicles or operating machinery while taking PTH 30mg Tablet is unsafe because in rare cases it may cause dizziness and seizures in some individuals.
Side Effects of Pth 30mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
· Numbness and tingling around the mouth
· Muscle cramps
· Swelling of the face, lips, mouth, tongue or throat
· Difficulty swallowing or breathing
· Allergic reactions
· Loss of appetite
· Muscle pain
· Low testosterone levels
· High potassium levels in the blood
· Upper respiratory infection
· Low BP
· Stomach and back pain
|Minimum Order Quantity
|Selpercatinib 40 Mg Capsule
|Non-small cell lung cancer
|Country of Origin
|Made in India
Selcaxen 40 Mg Generic Selpercatinib. Healthcare professionals prescribe Selcaxen 40 mg to treat certain medical conditions. It contains an active ingredient that helps regulate specific processes in the body. Patients typically take it orally, as directed by a doctor, and they may accompany it with food or take it on an empty stomach. It is important to follow the prescribed dosage and complete the full course of treatment. Like all drugs, Selcaxen 40 mg may cause side effects. It is advisable to seek personalized advice and guidance from a healthcare expert.
Each capsule contains Selpercatinib INN 40 mg.
Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
These drugs treat metastatic RET fusion-positive non-small cell lung cancer(NSCLC)in adult patients. Selpercatinib is utilized to treat metastatic RET fusion-positive non-small cell lung cancer in adults.
The regulatory authority has approved this indication through accelerated approval, considering the overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).RET-Mutant Medullary Thyroid Cancer
Selpercatinib is indicated for the treatment of adult ano pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroio cancer(MTC) who require systemic therapy.
Selpercatinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroic cancer who require systemic therapyand who are radioactive iodine-refractoryif radioactive iodine is appropriate).
The approval for this indication is granted through accelerated approval, considering the overall response rate and response duration. Ongoing approval depends on verifying and describing clinical benefits in confirmatory trial(s).”
Dosage And Administration Patient Selection
Select patients for treatment with Selpercatinib baseo on the presence of a RET genefusion(NSCLC O thvroid cancer)or specific RET genemutation(MTC)in tumor specimens or plasma. An FDA-approved test for the detection of RET gene fusions and RET gene mutations is not currently available.Important Administration Instructions
SELPERCATINIB may be taken with or without food unless co-administrated with a proton pumpinhibitor
The recommended dosage of Selpercatinib based on body weight is:
•Less than 50 kg:120mg50 kg or greater:160 mg
*Take Selpercatinib 2 hours before or 10 hours after administration of an H2receptor antagonist.
*Take Selpercatinib 2 hours before or 2 hours after administration of a locally-acting antacid.
Dosage Modifications for Adverse Reactions
The recommended dose reductions for adverse reactions are provided in Table 1) Dosage
Modifications for Adverse Reactions
The recommended dose reductions for adverse reactions are provided in Table 1.
· Hypertension (High Blood Pressure)
· Increased Liver Enzyme
· Muscle and Joint Pain